Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Relugolix Plus E2/NETA (Group A)	163
Overall Study	STARTED	Relugolix Plus Delayed E2/NETA (Group B)	150
Overall Study	STARTED	Placebo (Group C)	164
Overall Study	Received at Least 1 Dose of Study Drug	Relugolix Plus E2/NETA (Group A)	163
Overall Study	Received at Least 1 Dose of Study Drug	Relugolix Plus Delayed E2/NETA (Group B)	149
Overall Study	Received at Least 1 Dose of Study Drug	Placebo (Group C)	164
Overall Study	COMPLETED	Relugolix Plus E2/NETA (Group A)	133
Overall Study	COMPLETED	Relugolix Plus Delayed E2/NETA (Group B)	108
Overall Study	COMPLETED	Placebo (Group C)	122
Overall Study	NOT COMPLETED	Relugolix Plus E2/NETA (Group A)	30
Overall Study	NOT COMPLETED	Relugolix Plus Delayed E2/NETA (Group B)	42
Overall Study	NOT COMPLETED	Placebo (Group C)	42

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03412890/flow